Frontline therapy of ovarian cancer: trials and tribulations
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Obstetrics and Gynaecology
Reference48 articles.
1. First-line therapy in ovarian cancer trials;Thigpen;Int J Gynecol Cancer,2011
2. SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm;Herzog;Gynecol Oncol,2014
3. Cancer immunotherapy trials not immune from imprecise selection of patients;Garon;N Engl J Med,2017
4. Platinum compounds: a new class of potent antitumour agents;Rosenberg;Nature,1969
5. Mitotic inhibitors;Chabner;Cancer Chemother Biol Response Modif,1994
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Bioprospecting the Anticancer Efficacy of <i>Garcinia anomala</i> from North-East India in Ovarian Cancer Cells – An <i>In Vitro</i> Study;Journal of Endocrinology and Reproduction;2024-08-26
2. The potential feasibility of nab-paclitaxel as the first-line chemotherapy for ovarian cancer: clinical development and future perspectives;Archives of Gynecology and Obstetrics;2022-02-14
3. Why Precision Oncology Is Not Very Precise (and Why This Should Not Surprise Us);Personalized Medicine in the Making;2022
4. Model constructions of chemosensitivity and prognosis of high grade serous ovarian cancer based on evaluation of immune microenvironment and immune response;Cancer Cell International;2021-11-04
5. Physcion-8-O-β-d-glucoside interferes with the nuclear factor-κB pathway and downregulates P-glycoprotein expression to reduce paclitaxel resistance in ovarian cancer cells;Journal of Pharmacy and Pharmacology;2020-12-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3